Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.51 |
| ▸ | CTSS | P25774 | 3/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7138103 | 0.92 | CTSS (0.51) | CTSKCTSSPPARACTSLCTSB | |
| SCHEMBL7135411 | 0.88 | CTSK (0.63) | CTSKCTSSPPARACTSL | |
| SCHEMBL7135516 | 0.80 | CTSS (0.55) | CTSKCTSSPPARACTSLCTSB | |
| SCHEMBL7136265 | 0.79 | MEN1 (0.48) | CTSKCTSSCTSLCTSBKMT2A | |
| SCHEMBL18257547 | 0.79 | CTSD (0.56) | CTSKCTSSCTSLCTSBKMT2A | |
| SCHEMBL23616314 | 0.79 | CTSD (0.56) | CTSKCTSSCTSLCTSBKMT2A | |
| SCHEMBL7133774 | 0.78 | CTSS (0.63) | CTSKCTSSPPARACTSLCTSB | |
| SCHEMBL8961015 | 0.78 | ACE (0.60) | CTSKCTSSCTSLCTSBCA2 | |
| SCHEMBL8961019 | 0.78 | ACE (0.60) | CTSKCTSSCTSLCTSBCA2 | |
| SCHEMBL7137837 | 0.78 | CTSS (0.61) | CTSKCTSSPPARACTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | disclosed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, HPN, CTRL | CTSK 29/4885CTSS 9/4885PPARA 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.